Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha1H as Neoadjuvant Therapy in NMIBC
NCT07804056Phase 3Recruiting
- Sponsor
- Hamlet Pharma
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) comparing Alpha1H with Standard of Care (2 arms). Primary endpoint: Event-Free Survival up to 3 years. Started Sep 2026; status: recruiting.
02
Drugs
alpha1-oleate
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07804056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07804056.